Omega interferon: Completed Phase Ib enrollment

Intarcia disclosed that in December it completed enrollment of 60 patients in an open-label, dose-escalation, U.S. Phase Ib trial evaluating 25 and 50 µg of ITCA 638 implanted subcutaneously for 48 we...